Evidence‑Based Management of Oral Mucositis in Oncology Patients

Pain Management for Established Mucositis

Patient‑controlled analgesia (PCA) with morphine is recommended for oral‑mucositis pain in patients undergoing hematopoietic stem‑cell transplantation (HSCT) (Evidence level II). 1
0.2 % morphine mouthwash (5 mL, held in the mouth and slowly swallowed) is effective for pain control in head‑and‑neck cancer patients receiving chemoradiotherapy (Evidence level III). 2
Transdermal fentanyl can be used to relieve mucositis‑related pain in patients receiving conventional or high‑dose chemotherapy, with or without total‑body irradiation (Evidence level III). 1
0.5 % doxepin mouthwash (rinsed for 2 min, 4–8 times/day) provides additional analgesia for any type of oral mucositis (Evidence level IV). 1

Implement standardized oral‑hygiene protocols—including gentle tooth brushing, toothpaste use, and frequent rinses—to reduce the incidence of mucositis across all age groups and treatment modalities (Evidence level III). 1

Advise patients to avoid irritant foods (citrus, tomatoes, spicy, hot, raw, or crunchy items) (Evidence level III). 3
Counsel patients to refrain from tobacco and alcohol use (Evidence level III). 3
Recommend removal of dentures during oral‑care routines (Evidence level III). 3

Benzidamine 0.15 % mouthwash (15 mL held for 2 min, 4–8 times/day from treatment start) prevents mucositis in head‑and‑neck radiotherapy up to 50 Gy without concurrent chemotherapy (Evidence level I). 1
Rebamipide 4 % mouthwash (5 mL swished for 30 s, 6 times/day beginning 3 days before radiotherapy and continued for 3 months) can delay onset and lessen severity of radiotherapy‑induced mucositis (Evidence level II). 4
Low‑level laser therapy (LLLT) – wavelength 650 nm, power 40 mW, energy dose 2 J/cm² – reduces mucositis risk in HSCT patients receiving high‑dose chemotherapy with or without total‑body irradiation (Evidence level II). 1
LLLT (≈632.8 nm) is also suggested for head‑and‑neck radiotherapy without chemotherapy (Evidence level III). 2
Palifermin (recombinant human keratinocyte growth factor) – 60 µg/kg/day administered for 3 days before conditioning and 3 days after transplant – prevents oral mucositis in high‑dose chemotherapy + total‑body irradiation autologous HSCT (Evidence level II). An alternative regimen of 360 µg/kg given as six intravenous injections is also effective. 2
Oral cryotherapy (30 min) performed during bolus 5‑fluorouracil infusion prevents mucositis (Evidence level II); it is additionally beneficial for high‑dose melphalan conditioning before HSCT (Evidence level III). 1

Sucralfate mouthwash – not recommended for mucositis prevention or treatment in chemotherapy or radiotherapy settings (Evidence level I–II). 1
Intravenous glutamine – contraindicated for mucositis prophylaxis in high‑dose chemotherapy for HSCT (Evidence level II). 1
Iseganan mouthwash – should not be used for mucositis prevention in HSCT or head‑and‑neck radiotherapy (Evidence level II). 1
Chlorhexidine mouthwash – not advised for mucositis prevention in head‑and‑neck radiotherapy (Evidence level III). 1
GM‑CSF mouthwash – not recommended for mucositis prevention in stem‑cell transplantation (Evidence level II). 1

Patients should refrain from eating or drinking for 30 minutes after each magic‑mouthwash rinse to maximize local effect. 5, 6

Morphine 0.2 % mouthwash (5 mL held and slowly swallowed) provides superior pain relief compared with magic mouthwash in head‑and‑neck cancer patients with mucositis. Guideline recommendation. 7
Patient‑controlled analgesia with morphine is advised for hematopoietic stem‑cell transplantation (HSCT) patients experiencing mucositis‑related pain. Guideline recommendation. 8, 7
Transdermal fentanyl is recommended for systemic pain control when oral agents are insufficient. Guideline recommendation. 9

Benzydamine 0.15 % mouthwash (15 mL swished for 2 min, 4–8 times daily) is endorsed for preventing radiation‑induced mucositis up to 50 Gy. Guideline recommendation. 8, 7
Low‑level laser therapy is endorsed for prophylaxis of mucositis in HSCT and head‑and‑neck radiation patients. Guideline recommendation. 8, 9
Palifermin (60 µg/kg/day for 3 days before and after HSCT) is recommended to reduce the incidence and severity of mucositis. Guideline recommendation. 8, 9

Magic mouthwash should not be used beyond the acute mucositis period; prolonged use offers no additional benefit and may increase adverse effects. Guideline recommendation. 10, 5

Use a soft toothbrush after meals and before sleep to maintain oral hygiene. 5, 6
Rinse with an alcohol‑free mouthwash (15 mL, swish 1 min) at least four times daily. 5, 6
Avoid oral irritants such as tobacco, alcohol, citrus fruits, tomatoes, and spicy, hot, raw, or crusty foods. 5, 6
Maintain adequate hydration by drinking ample fluids throughout the day. 10, 5, 6
Remove dentures during all oral‑care procedures to reduce microbial load. 5, 6